PharmaCyte Biotech Releases New Video Highlighting Diabetes Treatment Development Program
December 15 2015 - 9:25AM
PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage
biotechnology company focused on developing targeted treatments for
cancer and diabetes using its signature live-cell encapsulation
technology, Cell-in-a-Box®, announced today that it has released a
new video that highlights PharmaCyte’s diabetes treatment
development program. PharmaCyte invited Stock Market Media to sit
in on its 2nd Annual International Diabetes Consortium in Vienna,
Austria, to document PharmaCyte’s story related to the development
of its treatment for Type 1 diabetes and insulin-dependent Type 2
diabetes.
The new video can be viewed on the PharmaCyte
website at: www.PharmaCyte.com/diabetes
In the video, viewers will hear from members of
the International Diabetes Consortium on PharmaCyte’s three-pronged
approach on the road to developing a successful treatment for Type
1 diabetes and Type 2 insulin-dependent diabetes. PharmaCyte plans
to encapsulate a human cell line that has been genetically modified
to produce, store and release insulin in response to blood glucose
levels in their surroundings. The encapsulation will be done using
the Cell-in-a-Box® technology.
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage
biotechnology company focused on developing and preparing to
commercialize treatments for cancer and diabetes based upon a
proprietary cellulose-based live cell encapsulation technology
known as “Cell-in-a-Box®.” This unique and patented technology will
be used as a platform upon which treatments for several types of
cancer and diabetes are being developed.
PharmaCyte’s treatment for cancer involves
encapsulating genetically modified live cells that convert an
inactive chemotherapy drug (ifosfamide) into its active or
“cancer-killing” form. These encapsulated live cells are placed as
close to a cancerous tumor as possible. Once implanted in a
patient, ifosfamide is then given intravenously at one-third the
normal dose. The ifosfamide is carried by the circulatory system to
where the encapsulated cells have been placed. When ifosfamide,
which is normally activated in the liver, comes in contact with the
encapsulated live cells, activation of the drug takes place at the
source of the cancer without any side effects from the
chemotherapy. This “targeted chemotherapy” has proven remarkably
effective and safe to use in past clinical trials.
In addition to developing a novel treatment for
cancer, PharmaCyte is developing a treatment for Type 1 diabetes
and Type 2 insulin-dependent diabetes. PharmaCyte plans to
encapsulate a human cell line that has been genetically engineered
to produce, store and release insulin in response to the levels of
blood sugar in the human body. The encapsulation will be done using
the Cell-in-a-Box® technology.
Safe Harbor
This press release may contain forward-looking statements
regarding PharmaCyte Biotech and its future events and results that
involve inherent risks and uncertainties. The words "anticipate,"
"believe," "estimate," "expect," "intend," "plan" and similar
expressions, as they relate to PharmaCyte or its management, are
intended to identify forward-looking statements. Important factors,
many of which are beyond the control of PharmaCyte, could cause
actual results to differ materially from those set forth in the
forward-looking statements. They include PharmaCyte's ability to
continue as a going concern, delays or unsuccessful results in
preclinical and clinical trials, flaws or defects regarding its
product candidates, changes in relevant legislation or regulatory
requirements, uncertainty of protection of PharmaCyte’s
intellectual property and PharmaCyte’s continued ability to raise
capital. PharmaCyte does not assume any obligation to update any of
these forward-looking statements.
More information about PharmaCyte can be found
at www.PharmaCyte.com. It can also be obtained by contacting
Investor Relations.
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856